Xeris Pharmaceuticals

XERSApproved

Xeris Pharmaceuticals is a publicly traded company (NASDAQ: XERS) that has built a commercial portfolio and pipeline around its novel formulation technologies designed to eliminate reconstitution and enable room-temperature stability of injectable drugs. The company's strategy involves both developing its own products and partnering with other biopharma companies to reformulate their injectables. With three FDA-approved products on the market and a pipeline of reformulation candidates, Xeris aims to address significant unmet needs in endocrinology, neurology, and rare diseases.

Market Cap

$938.0M

Employees

200-300

Focus

Biotech

XERS · Stock Price

USD 5.44+2.61 (+92.23%)

Historical price data

AI Company Overview

Technology Platform

Proprietary XeriSol™ and XeriJect™ platforms for formulating injectable drugs as highly concentrated, non-aqueous, ready-to-use liquids that are stable at room temperature.

Pipeline Snapshot

19 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Glucagon	Diabetes Mellitus, Type 1	Phase 3
G-Pen + Lilly Glucagon	Insulin Hypoglycemia	Phase 3
G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])	Hypoglycemia	Phase 3
G-Pen + Novo Glucagon	Insulin Hypoglycemia	Phase 3
Glucagon	Hypoglycemia	Phase 2

Funding History

Total raised: $200M

PIPE$50MUndisclosedJun 15, 2020

IPO$75MUndisclosedJul 26, 2018

Series C$45MUndisclosedDec 15, 2016

Series B$20MUndisclosedJun 15, 2014

FDA Approved Drugs

RECORLEVNDADec 30, 2021

GVOKE KITNDASep 10, 2019

GVOKE PFSNDASep 10, 2019

Opportunities

Significant growth opportunity lies in expanding market share for Gvoke in the competitive hypoglycemia rescue market and driving adoption of Keveyis and Recorlev in their respective rare disease niches.

The development of liquid glucagon (XP-8121) for use in automated insulin delivery systems represents a potentially transformative future revenue stream.

The proprietary formulation platforms also create a pipeline of partnership opportunities with other biopharma companies seeking to improve their injectable products.

Risk Factors

Key risks include intense commercial competition, particularly for Gvoke; the company's reliance on a small number of products for revenue; the ongoing need for capital to fund operations and growth; and the inherent risks of clinical development for pipeline candidates.

Integration and growth of the acquired Strongbridge assets are also critical.

Competitive Landscape

Xeris faces competition from large pharma (Eli Lilly) and specialized biotechs (Zealand Pharma) in the glucagon market, and from established players (Corcept, Recordati) in Cushing's syndrome. Its core differentiation is its proprietary formulation technology that enables room-temperature stable, ready-to-use injectables, addressing significant convenience and stability issues in drug delivery.

Publications

Patents

Pipeline

FDA Approvals